Enterprise Value
-32.64M
Cash
44.74M
Avg Qtr Burn
-6.138M
Short % of Float
0.64%
Insider Ownership
29.53%
Institutional Own.
55.71%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
NX-13 Details Ulcerative colitis | Phase 2 Data readout | |
Omilancor Details Eosinophilic Esophagitis | Failed Discontinued | |
Omilancor (BT-11) Details Atopic dermatitis | Failed Discontinued | |
LABP-104 Details Rheumatoid arthritis | Failed Discontinued | |
Omilancor (BT-11) Details Crohns disease | Failed Discontinued | |
LABP-104 Details Systemic lupus erythematosus | Failed Discontinued | |
NX-13 Details Crohns disease | Failed Discontinued | |
Omilancor (BT-11) Details Ulcerative colitis | Failed Discontinued |